Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

June 4, 2016

Sheraton Chicago Hotel & Towers
Chicago, Illinois

Targeting Advanced ER+ Metastatic Breast Cancer with CDK 4/6 Inhibitors

Clinical Considerations and Emerging Opportunities



Overview
Developing strategies to overcome endocrine resistance in breast cancer is critical to further enhance the benefit of existing therapies such as tamoxifen or an aromatase inhibitor (AI). One such strategy is use of cyclin-dependent kinase (CDK) 4/6  inhibitors. Three such agents have been investigated in this setting, including abemaciclib; palbociclib, which is FDA approved;  and ribociclib. This interactive symposium will feature expert faculty sharing clinical data, patient stories, and case challenges to discuss the mechanism of action and the clinical efficacy and safety information associated with these agents.
 

The Registration and Information Desk at the Sheraton Chicago Hotel & Towers will be staffed:

Saturday, June 4, 2016  6:30 pm – 8:30 pm

 

Faculty

Harold J. Burstein, MD, PhD
Dana Farber Cancer Institute
Boston, Massachusetts

Maura N. Dickler, MD
Memorial Sloan Kettering
New York, New York

Nicholas C. Turner, MBBS, PhD
Royal Marsden Hospital
London, England, United Kingdom

Scientific Agenda

Saturday, June 4, 2016

6:30 PM

Registration and Dinner

7:00 PM

Welcome and Pre-Assessment
Harold J. Burstein, MD, PhD

7:10 PM

Mechanistic Activity and Development History of CDK 4/6 Inhibitors
Harold J. Burstein, MD, PhD

7:20 PM

Current Clinical Data for CDK 4/6 Inhibitors in Breast Cancer
Nicholas C. Turner, MBBS, PhD

7:50 PM

Ongoing Investigations and Future Applications
Maura N. Dickler, MD

8:20 PM

Review of Registrant-Submitted Case Studies
All faculty

8:30 PM

Panel Q&A
All faculty

8:45 PM

Summary of Key Points & Post-Assessment
Harold J. Burstein, MD, PhD

9:00 PM

Adjourn

 

Continuing Medical Education


UNMC Logo
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Who Should Attend

This activity is designed to address the needs of medical oncologists, breast surgeons, and other clinicians involved and/or interested in the management of patients with metastatic breast cancer in the US.

Objectives

After successful completion of this activity, participants should be able to:

  • Correlate the mechanistic activity of CDK 4/6 inhibitors with the rationale for their use as targeted therapy for ER+ MBC
  • Assess current best practices for clinical use of CDK 4/6 inhibitors to treat ER+ MBC based on relevant data as interpreted by leading experts
  • Evaluate unmet needs in treating patients with MBC, including future applications of CDK 4/6 inhibitors

 

Support

Supported in part by an educational grant from Pfizer.

 

Registration

Registration is Complimentary

To Register: You may register online or by calling Imedex at +1 (800) 233 0957 (international callers please call +1 (678) 242 0906).  For assistance, please contact registration@imedex.com. Registration confirmations will be issued before the meeting.

Available seating will be based on room capacity. Seating is limited and pre-registration does not guarantee admission, as the room may be overbooked. Early arrival is recommended and seating will be first come first serve until capacity is met.

Please note that you must bring your ASCO badge for admittance to the symposium.

Imedex does not accept responsibility for covering travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

 

Organizer


11675 Rainwater Drive
Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
FacebookTwitterLinkedInEmail

For registration inquiries:
Tel.: +1 (678) 242 0906
Email: registration@imedex.com

Not an official event of the 2016 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.